KORU Medical Systems (KRMD)

Executive Summary

KORU Medical Systems is a U.S.-based medical device company focused on subcutaneous drug delivery via its proprietary Freedom™ Infusion System, which includes the Freedom60 and FreedomEDGE syringe infusion pumps and associated accessories. The company enables home-based therapy for patients with chronic conditions requiring regular infusions, such as primary immunodeficiency, autoimmune disorders, and other chronic diseases. With a shift toward ambulatory and self-administered treatments, KORU's portable devices offer a differentiated solution that improves patient quality of life and reduces healthcare costs. The company has a market valuation of approximately $190 million and trades under KRMD. KORU continues to expand its product portfolio and address the growing demand for large-volume subcutaneous delivery, targeting indications traditionally served by intravenous therapy. Its technology is supported by clinical evidence and has received regulatory clearances, positioning it to capture share in the expanding home infusion market. KORU's growth strategy centers on broadening indication approvals, forging partnerships with pharmaceutical companies developing subcutaneous formulations, and advancing its next-generation pump technologies. The company faces competition from established infusion pump manufacturers but benefits from its niche focus on high-volume subcutaneous delivery and ease of use. With an aging population and increasing prevalence of chronic diseases, the addressable market is significant. However, adoption depends on clinical outcomes, reimbursement coverage, and physician preference. KORU's recent revenue trends and pipeline progress suggest moderate near-term growth potential, though profitability remains a focus. Overall, KORU represents a specialized opportunity in the drug delivery space with a defensible product and clear market need.

Upcoming Catalysts (preview)

• 2026 Q4FDA Clearance of Next-Generation FreedomEDGE Pump Enhancements75% success
• 2027 Q1Major Pharma Partnership for Subcutaneous Delivery of a Blockbuster Biologic40% success
• 2027 Q2Achievement of Operating Cash Flow Breakeven55% success